Edwards Lifesciences Sees Strong 2Q Due to Ongoing SAPIEN Adoption

Edwards Lifesciences posted strong second quarter results largely due to ongoing growth in sales of transcatheter heart valves, the company revealed in a Thursday earnings report. The company’s net sales jumped 7.3 percent over last year to $517 million during the second quarter. Sales of transcatheter heart valves, meanwhile, were $182 million for the quarter, up 25 percent over the same time last year.
Devices & Diagnostics Letter